ETIDRONATE DISODIUM - Generic Drug Details

What are the generic drug sources for etidronate disodium and what is the scope of patent protection?

Etidronate disodium is the generic ingredient in two branded drugs marketed by Mgi Pharma Inc, Apil, and Pharmobedient, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for ETIDRONATE DISODIUM

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3
Drug Master File Entries:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	863
Drug Prices:	Drug price trends for ETIDRONATE DISODIUM
DailyMed Link:	ETIDRONATE DISODIUM at DailyMed

See drug prices for ETIDRONATE DISODIUM

Recent Clinical Trials for ETIDRONATE DISODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
UMC Utrecht	Phase 2
Netherlands Brain Foundation	Phase 2

See all ETIDRONATE DISODIUM clinical trials

US Patents and Regulatory Information for ETIDRONATE DISODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pharmobedient	ETIDRONATE DISODIUM	etidronate disodium	TABLET;ORAL	075800-001	Jan 24, 2003		DISCN	No	No
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pharmobedient	ETIDRONATE DISODIUM	etidronate disodium	TABLET;ORAL	075800-002	Jan 24, 2003		DISCN	No	No
Mgi Pharma Inc	DIDRONEL	etidronate disodium	INJECTABLE;INJECTION	019545-001	Apr 20, 1987		DISCN	No	No

Expired US Patents for ETIDRONATE DISODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mgi Pharma Inc	DIDRONEL	etidronate disodium	INJECTABLE;INJECTION	019545-001	Apr 20, 1987	3,683,080
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-001	Approved Prior to Jan 1, 1982	4,254,114
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-002	Approved Prior to Jan 1, 1982	3,524,844
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-001	Approved Prior to Jan 1, 1982	4,216,211
Mgi Pharma Inc	DIDRONEL	etidronate disodium	INJECTABLE;INJECTION	019545-001	Apr 20, 1987	4,254,114
Mgi Pharma Inc	DIDRONEL	etidronate disodium	INJECTABLE;INJECTION	019545-001	Apr 20, 1987	4,216,211

Last updated: August 13, 2026

Etidronate disodium is a mature, low-revenue bisphosphonate with limited remaining commercial upside. Its market has shifted from branded osteoporosis therapy to generic, hospital, and niche metabolic use. The principal commercial constraints are weak pricing, replacement by newer bisphosphonates, limited promotional activity, and the absence of meaningful patent or regulatory exclusivity. Public companies generally do not report etidronate revenue separately, so its financial trajectory is best assessed through product availability, indication erosion, generic competition, and therapeutic substitution.

Etidronate Disodium Market Dynamics, Patent Status, and Financial Trajectory

What is etidronate disodium used for?

Etidronate disodium is an oral and injectable bisphosphonate historically used to treat Paget's disease of bone, postmenopausal osteoporosis, heterotopic ossification, and selected hypercalcemia-related conditions. In the United States, the former branded product was Didronel, marketed by Norwich Eaton and later associated with Procter & Gamble's pharmaceutical operations.

Etidronate is a first-generation, non-nitrogen-containing bisphosphonate. Unlike newer agents such as alendronate, risedronate, ibandronate, and zoledronic acid, it does not inhibit farnesyl pyrophosphate synthase. Its lower potency and the risk of defective mineralization at excessive or continuous doses limited its use in osteoporosis and encouraged the adoption of later-generation products.

Attribute	Etidronate disodium
Drug class	First-generation bisphosphonate
Active ingredient	Etidronate disodium
Former U.S. brand	Didronel
Main historical uses	Paget's disease, osteoporosis, heterotopic ossification
Dosage forms	Tablets and injectable formulations in selected markets
FDA approval era	Late 1970s
Current commercial position	Mature generic and niche product
Biosimilar exposure	None
Patent value	No material composition-of-matter value remaining
Primary competitive threat	Therapeutic substitution by newer bisphosphonates

The FDA label identifies Paget's disease as a principal indication and describes cyclical dosing for osteoporosis and other conditions. Continuous exposure can impair bone mineralization, which is a central clinical limitation of etidronate therapy.[1]

How large is the etidronate disodium market?

The global market for etidronate disodium is small relative to the overall osteoporosis and bisphosphonate markets. Public financial disclosures do not generally identify etidronate revenue as a separate line item. The product is typically embedded in broader generic, hospital, or specialty pharmaceutical revenue.

Market demand is concentrated in four areas:

1. Legacy treatment of Paget's disease.
2. Use where clinicians retain experience with the product.
3. Hospital or institutional treatment of heterotopic ossification.
4. Markets where newer bisphosphonates are less available or less affordable.

The largest commercial opportunity in bone health has moved toward branded and generic alendronate, risedronate, zoledronic acid, and newer agents such as denosumab and anabolic therapies. Etidronate has not maintained a comparable position because it has lower potency, less convenient dosing, and fewer modern guideline advantages.

Market segmentation by use

Segment	Commercial outlook	Main reason
Paget's disease	Stable but small	Chronic niche population and limited patient volume
Osteoporosis	Declining	Replaced by alendronate, risedronate, zoledronic acid, and denosumab
Heterotopic ossification	Niche	Use is specialized and often institutional
Hypercalcemia	Limited	Newer agents and disease-specific treatments compete
Research or off-label use	Minimal	No meaningful commercial scale

Paget's disease remains the most defensible clinical niche. Even there, treatment duration is often intermittent, limiting repeat prescription volume. Osteoporosis has the largest historical patient population but is the least attractive segment for etidronate because newer agents offer stronger fracture-prevention positioning and more established dosing protocols.

What is the financial trajectory for etidronate disodium?

Etidronate disodium has a long-term declining or flat-low trajectory rather than a growth trajectory. Its revenue profile is determined by volume retention in niche indications, generic price erosion, and supplier continuity.

The financial pattern can be summarized as follows:

Period	Financial trajectory	Market driver
1970s-1980s	Commercial expansion	Initial adoption for Paget's disease and osteoporosis
1990s	Peak strategic relevance	Broad bisphosphonate use before major generic substitution
2000s	Decline	Entry and adoption of alendronate, risedronate, and other agents
2010s	Mature generic phase	Low prices and limited promotion
2020s	Low-volume maintenance	Niche demand, supplier availability, and therapeutic substitution

The former branded opportunity has largely disappeared. Any remaining revenue is likely generated through low-margin generic sales, institutional contracts, or regional distribution. The market does not support substantial brand investment, broad clinical development, or large-scale sales infrastructure.

Revenue exposure for manufacturers

Etidronate is unlikely to create material revenue exposure for diversified pharmaceutical companies. A manufacturer may retain the product because of:

• Low incremental manufacturing cost.
• Existing regulatory approval.
• Hospital or distributor contracts.
• Portfolio completeness in generic bone-health products.
• Stable demand from a small group of prescribers.

The product can still have strategic value in a narrow portfolio, but its absolute revenue contribution is expected to be small. A supplier's financial risk is more likely to arise from discontinuation, manufacturing economics, or shortage-related demand than from patent competition.

When did etidronate disodium lose exclusivity?

Etidronate's original U.S. regulatory and patent exclusivity expired decades ago. The product was approved in the late 1970s, and the relevant composition and early-use protection is no longer commercially meaningful.

The current competitive structure is generic. The key commercial questions are not patent expiry or Paragraph IV timing, but whether approved manufacturers continue to supply the product and whether demand justifies production.

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Original composition patent protection	Expired
Branded product exclusivity	Expired
Pediatric exclusivity	Not commercially relevant
Orphan exclusivity	No meaningful current role
Data exclusivity	Expired
Patent term extension	No current commercial significance
Biosimilar exclusivity	Not applicable

No credible commercial thesis depends on restoring exclusivity for the active ingredient. Any new protection would need to come from a genuinely differentiated formulation, delivery system, or method of treatment, and the low market value would make such development difficult to justify.

What is the Orange Book status of etidronate disodium?

Etidronate disodium is a small-molecule generic product, not a biologic. Its relevant FDA reference-product and abbreviated new drug application history is therefore distinct from biosimilar regulation.

The Orange Book's current listing status can vary by product, strength, manufacturer, and marketing status. A product may appear with a discontinued or withdrawn status even when the active ingredient remains available from another supplier. A historical listing does not establish active commercial supply.

The practical Orange Book conclusions are:

• Etidronate does not have a commercially meaningful active patent estate.
• Generic competition is established.
• Paragraph IV litigation is not a significant current market driver.
• A new abbreviated application would face a mature, low-value market rather than a protected branded market.
• Product availability must be assessed at the manufacturer and strength level.

The FDA's Orange Book identifies approved drug products and patent or exclusivity information, while DailyMed provides current labeling and package information for products distributed in the United States.[2,3]

Are there Paragraph IV challenges involving etidronate disodium?

Paragraph IV litigation has little current strategic relevance for etidronate disodium. The product's original exclusivity period expired long ago, and the market is not structured around a high-value branded reference product.

A generic entrant could theoretically challenge a listed patent if an applicable patent remained in the Orange Book. In practice, the commercial incentives are weak because:

• The active ingredient is old.
• The market is small.
• Generic pricing is already compressed.
• New entrants would face limited upside.
• The product has substantial therapeutic substitutes.
• Litigation costs could exceed expected market returns.

No current high-value patent dispute is a material driver of the etidronate market based on the product's mature generic status. Any historical ANDA litigation would have limited impact on present revenue expectations.

What patents protect etidronate disodium?

No active composition-of-matter patent is expected to protect etidronate disodium in the United States. The original active ingredient and its basic therapeutic use are long out of patent term.

Potentially relevant protection could theoretically involve:

• A specific dosage regimen.
• A controlled-release formulation.
• A combination product.
• A manufacturing process.
• A specialized injectable formulation.
• A method for preventing heterotopic ossification.

These categories do not create a material current barrier unless a live, enforceable patent covers a commercially important product and is listed or otherwise actionable in the relevant jurisdiction. For the legacy product, the market's low value reduces the likelihood that formulation or process patents would support meaningful exclusivity.

How strong is the patent estate?

The patent estate is weak from a business-development perspective.

Patent factor	Assessment
Composition-of-matter protection	Expired
Core therapeutic use	Expired or commercially nonexclusive
Formulation protection	Limited commercial relevance
Manufacturing protection	Possible in theory, low strategic value
Patent litigation leverage	Low
Freedom-to-operate risk	Generally low for standard generic supply
Extension opportunity	Limited
Licensing value	Minimal

A company evaluating an etidronate product should focus on regulatory status, supply reliability, manufacturing cost, and market access rather than patent exclusivity.

What formulations are protected by etidronate patents?

The principal historical formulation was the oral tablet. Injectable or parenteral formulations have been used in certain markets and clinical settings, but formulation differentiation has not produced a durable commercial franchise comparable to long-acting or modified-release products.

The standard tablet is vulnerable to generic substitution. A new formulation would require evidence of meaningful clinical or adherence value, such as:

• Reduced dosing complexity.
• Lower gastrointestinal exposure.
• Improved bioavailability.
• Better control of bone mineralization effects.
• Hospital-use convenience.
• A differentiated delivery profile.

The economic case is weak because the target market is small and physicians can substitute among established bisphosphonates. A reformulated product would need a strong clinical advantage to support premium pricing.

What FDA regulatory issues affect etidronate disodium?

The main regulatory issues are product availability, labeling maintenance, manufacturing compliance, and clinical positioning.

Etidronate's known regulatory limitations include dose-cycle requirements and the risk of impaired bone mineralization with inappropriate continuous use. The FDA labeling also includes contraindications and precautions relevant to renal function, hypocalcemia, and skeletal mineralization.[1]

Regulatory risk factors

Regulatory issue	Commercial impact
Low demand	May lead manufacturers to discontinue products
Limited suppliers	Increases shortage or interruption risk
Legacy labeling	May reduce competitiveness against newer agents
Dose complexity	Reduces adherence and prescribing preference
Generic manufacturing	Creates dependence on cost-efficient production
Clinical substitution	Reduces incentive for label expansion

Because etidronate is an old small molecule, regulatory risk is operational rather than exclusivity-based. A manufacturer must maintain compliant facilities, validated processes, accurate labeling, and reliable supply despite limited revenue.

Which companies compete with etidronate disodium?

Competition comes primarily from therapeutic substitutes rather than direct etidronate manufacturers.

Direct and indirect competitors

Competitor	Active ingredient	Competitive position
Generic alendronate	Alendronate	Low-cost first-line osteoporosis alternative
Fosamax, historical brand	Alendronate	Established clinical reference product
Generic risedronate	Risedronate	Alternative oral bisphosphonate
Actonel, historical brand	Risedronate	Historical branded competitor
Reclast	Zoledronic acid	Intravenous dosing and high potency
Boniva	Ibandronate	Alternative dosing schedule
Prolia	Denosumab	Non-bisphosphonate antiresorptive
Evenity	Romosozumab	Anabolic and antiresorptive activity
Forteo and generics	Teriparatide	Bone-forming therapy

Alendronate is the most important low-cost substitute in osteoporosis. Zoledronic acid competes where annual intravenous dosing, potency, or adherence is important. Denosumab competes in patients who cannot use or do not respond adequately to oral bisphosphonates.

Etidronate retains limited differentiation in clinical familiarity and certain niche indications, but those advantages do not offset its broader commercial disadvantages.

What generic entry risks exist for etidronate disodium?

The product has already experienced generic entry. The current risk is not an initial generic launch but further supplier consolidation and price competition.

Generic market risks

1. A manufacturer may exit because annual volume is too low.
2. A limited number of suppliers may create intermittent shortages.
3. Contracting pressure may reduce gross margins.
4. Hospitals and wholesalers may favor alternative products.
5. Prescribers may switch permanently to newer bisphosphonates.
6. A new entrant may further reduce prices without expanding total demand.

The probability of a profitable, large-scale generic launch is low. A new entrant would need to secure a dependable supply chain and obtain sufficient volume from wholesalers, hospitals, or specialty distributors. The market is more suitable for a focused generic portfolio than for a standalone launch.

What manufacturing and intellectual-property barriers affect supply?

Manufacturing barriers are moderate operationally but low from an intellectual-property standpoint.

Etidronate disodium is a chemically defined small molecule. The basic active ingredient does not present the complexity of a biologic or highly specialized peptide. The main barriers are:

• Sourcing and quality control of raw materials.
• Process validation.
• Stability and dissolution testing.
• Low-volume batch economics.
• Packaging and labeling compliance.
• Distribution through declining channels.
• Maintaining supply despite weak demand.

The absence of strong patent barriers makes entry technically feasible, but the small market makes commercial entry unattractive. This is a common pattern for legacy medicines: low scientific complexity but weak return on manufacturing investment.

What licensing deals involve etidronate disodium?

Etidronate disodium has limited current licensing value. The major commercial licensing opportunities associated with the product were tied to historical brand commercialization, manufacturing rights, or regional distribution. Those arrangements do not create a contemporary growth platform.

A new license would likely be justified only for:

• Regional generic distribution.
• Hospital supply contracts.
• A differentiated formulation.
• A combination product.
• A manufacturing transfer in a jurisdiction with persistent demand.

There is no obvious basis for a large strategic licensing transaction involving standard etidronate tablets. Any current deal would likely be small, supply-oriented, and territory-specific.

What is the outlook for etidronate disodium through 2030?

The base case is continued market contraction with intermittent stability in niche indications.

Scenario	Probability assessment	Expected outcome
Base case	Most likely	Low-volume generic maintenance and gradual decline
Upside case	Low	Temporary demand increase from supply disruption or niche contracting
Downside case	Meaningful	Manufacturer withdrawal, reduced availability, or broader substitution
Innovation case	Very low	Reformulation creates limited specialty value

A rebound in osteoporosis use is unlikely without a new clinical or commercial proposition. The product is too old to benefit from conventional lifecycle management, and the treatment category has moved toward more potent or convenient agents.

Revenue exposure should therefore be modeled as a declining tail asset. Forecasts should use prescription volume, unit price, and supplier count rather than assuming branded growth. Margin assumptions should reflect generic competition and possible manufacturing inefficiency at low scale.

How does etidronate compare with newer bisphosphonates?

Factor	Etidronate	Alendronate	Zoledronic acid
Generation	First	Second	Third
Nitrogen-containing	No	Yes	Yes
Osteoporosis role	Limited	Established	Established
Dosing convenience	Lower	Oral weekly or other schedules	Intravenous, often annual
Potency	Lower	Higher	High
Generic competition	Mature	Mature	Mature
Patent value	None material	None material for core drug	Product and formulation history, largely expired
Commercial outlook	Declining niche	Large generic market	Durable specialty and generic market

Etidronate's principal disadvantage is not price. It is the combination of lower potency, less convenient dosing, narrower contemporary use, and clinical replacement.

Key Takeaways

• Etidronate disodium is a mature, low-value generic bisphosphonate.
• Its former branded market has been replaced by generic alendronate, risedronate, zoledronic acid, and non-bisphosphonate therapies.
• Paget's disease and selected hospital uses are the main remaining commercial niches.
• No meaningful active composition-of-matter or exclusivity position remains.
• Paragraph IV litigation is not a material current market factor.
• Public companies do not generally report standalone etidronate revenue.
• The financial trajectory is flat-to-declining, with revenue driven by niche volume and supply continuity.
• Manufacturing and supply risks are more relevant than patent risks.
• A new standard-tablet generic launch would likely have limited return potential.
• A differentiated formulation or specialty distribution strategy would be required to create meaningful value.

FAQs

Is etidronate disodium still available in the United States?

Availability depends on the manufacturer, dosage strength, and current marketing status. Historical FDA approval does not guarantee continuous commercial supply. DailyMed and FDA product databases are the relevant sources for current labeling and marketed-product information.[2,3]

Is etidronate disodium the same as alendronate?

No. Both are bisphosphonates, but etidronate is a first-generation non-nitrogen-containing compound, while alendronate is a more potent nitrogen-containing bisphosphonate with a broader modern osteoporosis role.

Does etidronate disodium have biosimilar competition?

No. Etidronate disodium is a chemically synthesized small molecule. It competes through generic-drug pathways rather than the FDA biosimilar pathway.

Can etidronate disodium still be used for osteoporosis?

It has historical osteoporosis use, but newer bisphosphonates and other therapies are generally more prominent in contemporary treatment strategies. Clinical selection depends on the indication, dosing cycle, patient risk, and applicable labeling.

Is etidronate disodium an attractive licensing asset?

Standard etidronate disodium is generally a weak licensing asset because the market is small, exclusivity has expired, and therapeutic substitution is extensive. Value could exist in a specific territory, supply arrangement, or differentiated formulation, but not in the unmodified legacy product alone.

References

1. U.S. Food and Drug Administration. (n.d.). Didronel (etidronate disodium) prescribing information. FDA-approved labeling.

2. U.S. National Library of Medicine. (n.d.). DailyMed: Etidronate disodium drug labeling. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. National Osteoporosis Foundation. (2022). Clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International.

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.